Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Monza – page 49

2 831 clinical trials in Monza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Monza at a glance
2 831
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 831 trials in Monza

Open in trial search

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Follicular lymphoma

Recruiting

Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Colorectal cancer

Recruiting

Study of Telisotuzumab Adizutecan for Adults with Colorectal Cancer Who Have Positive Circulating Tumor DNA After Treatment but No Visible Cancer on Scans

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Telisotuzumab adizutecan
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Malignant melanoma

Recruiting

Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Replimune Inc.

Endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Colorectal cancer metastatic

Recruiting

Study on the Safety and Effectiveness of Telisotuzumab Adizutecan and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

Endometrial cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

End stage renal disease

Recruiting

Study on the Safety and Effectiveness of PolyCore (Xylitol, L-Carnitine, Polydextrin) for Patients with End-Stage Kidney Disease Starting Peritoneal Dialysis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lactic Acid
  • Sponsor:Iperboreal Pharma S.r.l.

Psoriatic arthropathy

Recruiting

Study on the Effectiveness of Ixekizumab for Patients with Refractory Psoriatic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ixekizumab
  • Sponsor:University Hospital Of Ferrara

Primary biliary cholangitis

Recruiting

Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Immune thrombocytopenia

Recruiting

Study on the Safety and Effectiveness of Pirtobrutinib for Adults with Immune Thrombocytopenia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Monza

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments and novel approaches for lymphoma management. Studies include targeted therapies and immunotherapy combinations.

  • NSCLC Treatment Studies
  • Lymphoma Therapy Innovations
  • Breast Cancer Research

Advanced investigations into personalized treatment approaches for various cancer types using targeted therapies and immunological interventions.

02 Autoimmune Conditions

Research focusing on psoriatic arthritis and multiple sclerosis, evaluating novel biological treatments and their effectiveness in managing disease progression.

  • Inflammatory Disease Studies
  • Biomarker Research
  • Treatment Response Evaluation

Comprehensive studies examining new therapeutic approaches for chronic autoimmune conditions.

03 Infectious Diseases

Vaccine development studies targeting Herpes Zoster and Cytomegalovirus, focusing on prevention and immune response in different age groups.

  • Vaccine Efficacy Studies
  • Long-term Immunity Research
  • Viral Prevention Strategies

Advanced clinical trials evaluating new vaccination approaches and therapeutic strategies.

04 Cardiovascular Studies

Innovative research on heart failure prevention and pulmonary arterial hypertension, testing new therapeutic combinations and treatment approaches.

  • Preventive Cardiology
  • Hypertension Management
  • Drug Combination Studies

Investigation of novel therapeutic strategies for cardiovascular disease management and prevention.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.